IM Cannabis Corp
IMCC
Company Profile
Business description
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
Contact
Central District
Kibbutz Glil Yam4690500
ISRT: +972 773603504
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
55
Stocks News & Analysis
stocks
Ask the analyst: Can this genius product create the next ASX software king?
SiteMinder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.
stocks
Impact of ANZ’s huge fine
Working to prevent repeated failures could also improve competitiveness.
stocks
Acquisition a sign of weakness for overvalued ASX share
Acquisition unlikely to improve prospects in the US and detracts from other opportunities.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,094.90 | 27.60 | -0.30% |
| CAC 40 | 7,786.98 | 31.24 | -0.40% |
| DAX 40 | 23,359.18 | 29.94 | 0.13% |
| Dow JONES (US) | 45,984.36 | 226.46 | 0.49% |
| FTSE 100 | 9,208.37 | 12.71 | 0.14% |
| HKSE | 26,908.39 | 469.88 | 1.78% |
| NASDAQ | 22,243.38 | 90.57 | -0.41% |
| Nikkei 225 | 44,790.38 | 111.89 | -0.25% |
| NZX 50 Index | 13,228.38 | 6.51 | -0.05% |
| S&P 500 | 6,595.65 | 11.11 | -0.17% |
| S&P/ASX 200 | 8,818.50 | 30.00 | -0.34% |
| SSE Composite Index | 3,876.34 | 14.48 | 0.37% |